07 April 2026
07 April 2026
Synchrony is offered with SynX, a cloud-based app compliant with HIPAA and GDPR standards.
The UPBEAT clinical trial will enrol adults diagnosed genetically with BAG3-associated DCM.
The acquisition allows Neurocrine to offer three therapies: Ingrezza, Crenessity, and Vykat XR.
Zeto New Wave supports short-term EEG recordings up to 2.5 hours and allows clinics to deliver timely care.
The combination showed a trend towards improved overall survival compared with TACE alone.
The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
